The estimated Net Worth of Chris Vazquez is at least $20.4 Mille dollars as of 8 August 2024. Chris Vazquez owns over 602 units of Biodesix Inc stock worth over $20,401 and over the last few years Chris sold BDSX stock worth over $0.
Chris has made over 6 trades of the Biodesix Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Chris exercised 602 units of BDSX stock worth $1,078 on 8 August 2024.
The largest trade Chris's ever made was exercising 5,296 units of Biodesix Inc stock on 8 February 2024 worth over $9,480. On average, Chris trades about 940 units every 37 days since 2023. As of 8 August 2024 Chris still owns at least 11,397 units of Biodesix Inc stock.
You can see the complete history of Chris Vazquez stock trades at the bottom of the page.
Chris's mailing address filed with the SEC is 919 WEST DILLON RD, , LOUISVILLE, CO, 80027.
Over the last 4 years, insiders at Biodesix Inc have traded over $0 worth of Biodesix Inc stock and bought 32,782,268 units worth $58,800,766 . The most active insiders traders include Jack W Schuler, Lawrence T. Jr Kennedy e Matthew Strobeck. On average, Biodesix Inc executives and independent directors trade stock every 12 days with the average trade being worth of $567,788. The most recent stock trade was executed by Chris Vazquez on 8 August 2024, trading 602 units of BDSX stock currently worth $1,078.
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
Biodesix Inc executives and other stock owners filed with the SEC include: